CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT04269213
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸SUNY Upstate Medical Center, Syracuse, New York, United States
🇺🇸Allegheny Health Network Cancer Institute - West Penn Hospital, Pittsburgh, Pennsylvania, United States
Pharmacokinetics, Subjective Effects, and Abuse Liability of Nicotine Salt-Based Vaping Products With Tobacco or Unflavored E-liquids, SALTVAPE Study
Not Applicable
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT04231539
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT04207190
- Locations
- 🇺🇸
University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
Phase 2
Withdrawn
- Conditions
- Microsatellite StableMismatch Repair ProficientStage IIIB Colorectal Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8Stage IV Colorectal Cancer AJCC v8Stage IVA Colorectal Cancer AJCC v8Stage IVB Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Refractory Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2019-10-08
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Roswell Park Cancer Institute
- Registration Number
- NCT04119830
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2023-04-10
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 14
- Registration Number
- NCT04110249
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Phase 2
Active, not recruiting
- Conditions
- Advanced Colorectal CarcinomaMetastatic Colon AdenocarcinomaRecurrent Colorectal AdenocarcinomaStage III Colorectal Cancer AJCC v8Stage IV Colon Cancer AJCC v8Stage III Rectal Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IVB Colon Cancer AJCC v8Unresectable Colon AdenocarcinomaRecurrent Rectal Adenocarcinoma
- Interventions
- First Posted Date
- 2019-10-01
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 42
- Registration Number
- NCT04109924
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma
Phase 2
Active, not recruiting
- Conditions
- Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Esophageal Adenocarcinoma AJCC v8Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8Clinical Stage III Esophageal Adenocarcinoma AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8
- Interventions
- First Posted Date
- 2019-09-20
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT04097028
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, United States
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
- First Posted Date
- 2019-09-18
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT04093323
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Phase 1
Completed
- Conditions
- HER2/Neu NegativeProgesterone Receptor NegativePrognostic Stage IB Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Anatomic Stage IB Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Prognostic Stage II Breast Cancer AJCC v8Prognostic Stage IA Breast Cancer AJCC v8Triple-Negative Breast CarcinomaAnatomic Stage IIA Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 9
- Registration Number
- NCT04081389
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 50
- Registration Number
- NCT04073745
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
© Copyright 2024. All Rights Reserved by MedPath